Digital Health Investment Grows Up: What Comes After the Pandemic Boom

Remember when every app promised to fix healthcare? A few years ago, a good pitch deck and a telehealth idea could unlock serious venture capital. That gold rush has cooled considerably, and what's replacing it looks a lot more grounded in whether these tools actually help people get and stay well.

Neil Patel, head of ventures at Redesign Health, has watched this shift up close. In a recent conversation with HIMSS TV, he laid out how digital health investment has evolved since the COVID-19 pandemic, and what today's investors actually look for when deciding which healthcare companies deserve their money. His answer boils down to something refreshingly simple: durability over dazzle.

Think of the pandemic-era boom like a sugar rush. Lockdowns forced patients and providers alike into virtual visits almost overnight. Investors, seeing a captive audience desperate for remote care options, rushed to fund anything that looked like a solution. Telehealth platforms, remote monitoring startups, mental health apps: money flowed toward companies that could move fast, regardless of whether their underlying business made sense once the emergency passed.

That urgency has faded, but the need for good digital health tools hasn't. Patel's framing suggests the market is now sorting out which companies solved a real problem and which ones simply capitalized on a moment. That's a healthy correction, even if it stings for companies built on hype rather than substance.

From Novelty to Necessity

The distinction matters because patients are the ones who bear the consequences when a digital health tool disappears mid-treatment. Picture someone managing a chronic condition through a remote monitoring app, only to have that company shut down because its funding dried up. The technology wasn't the problem. The business model was.

Patel's comments point toward a more disciplined investment climate, one where next-generation healthcare companies need to prove staying power, not just early buzz. That likely means demonstrating clear clinical outcomes, sustainable revenue paths, and integration with existing health systems rather than operating as flashy standalone apps that never quite connect to a patient's actual care team.

This kind of scrutiny is a good thing for the field, even though it slows things down. Digital health tools that survive this tougher evaluation are more likely to still be around in five years, still serving patients, still improving outcomes. Investors asking harder questions now means fewer abandoned platforms and broken continuity of care later.

It also reflects something broader happening across health systems: a growing recognition that innovation without infrastructure is fragile. A brilliant app that can't talk to a hospital's electronic health record, or that lacks a plan for reimbursement, is a novelty. One that solves a workflow problem for clinicians while genuinely improving a patient's experience is something closer to necessity. Investors like Redesign Health appear to be betting on the latter.

The context here matters too. Related coverage from Healthcare IT News shows this evaluation extends well beyond investment decisions. Questions about what belongs in a patient's medical record in the age of artificial intelligence, for instance, get at a similar tension: as AI tools generate more data and more insights, health systems have to decide what's clinically meaningful versus what's just noise. The same discipline Patel describes for investors, separating genuine value from digital clutter, is playing out across clinical documentation, cybersecurity, and revenue cycle management as well.

Cybersecurity is a case in point. OpenAI and dozens of other companies recently warned of a "limited window" to strengthen cyber defenses, a reminder that digital health infrastructure is only as trustworthy as its weakest link. Healthcare organizations are also grappling with what one recent report called a "remediation challenge," the unglamorous but essential work of patching vulnerabilities before they become breaches. None of this is as exciting as a slick new app demo. All of it determines whether digital health tools can be trusted with people's most sensitive information.

Taken together, these threads suggest an industry maturing past its early enthusiasm. The pandemic proved that digital health could scale fast. The years since have been about proving it can also be safe, sustainable, and genuinely useful, not just novel.

Why It Matters

For patients, this recalibration isn't abstract. It shapes whether the telehealth platform they rely on will still exist next year, whether their health data stays protected, and whether the apps clinicians recommend actually integrate into their care rather than existing as disconnected add-ons. Investment decisions made in boardrooms eventually show up in exam rooms and living rooms, in whether a remote monitoring device keeps working or a mental health app stays affordable.

There's also a long-term consequence worth sitting with. If investors overcorrect and become too conservative, promising early-stage innovations that need patient capital to prove themselves might struggle to get funded at all. The goal isn't to kill risk-taking. It's to direct it toward companies solving real clinical and access problems, not just riding a temporary wave of pandemic-driven demand.

Patel's insights, framed around what makes a healthcare company built to last, offer a useful lens for anyone trying to make sense of where digital health goes next. The pandemic showed how quickly the industry could adapt. What comes next will show whether it can also endure, delivering care that people can depend on, not just technology that once felt exciting.